Holen Sie sich die Stockscreener-App
0.39
12.68%
0.0439
Handel nachbörslich:
.39
Equillium Inc Aktie (EQ) Neueste Nachrichten
Equillium expands equity incentive plan by 1.78 million shares - Investing.com Canada
Equillium Holds Annual Stockholders Meeting on Key Proposals - TipRanks
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - BioSpace
Renaissance Technologies LLC Sells 59,773 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - BioSpace
FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter
Equillium shares fall following FDA feedback By Investing.com - Investing.com India
Equillium shares fall following FDA feedback - Investing.com Australia
Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus
Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada
Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval - Investing.com
Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st
Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World
Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World
The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter
Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe
Breakthrough GVHD Treatment: New Drug Extends Response Duration by 4.7x in Phase 3 Trial - Stock Titan
Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):